Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, applying to the generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Paroxetine (Paroxetine hydrochloride)

Snippet

SUPPL AP for PAROXETINE (PAROXETINE HYDROCHLORIDE)